The EVP, Commercial of Seattle Genetics (SGEN) is Selling Shares


Yesterday, the EVP, Commercial of Seattle Genetics (SGEN), Darren Cline, sold shares of SGEN for $440.2K.

Following Darren Cline’s last SGEN Sell transaction on November 21, 2018, the stock climbed by 5.3%. In addition to Darren Cline, one other SGEN executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Seattle Genetics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $169 million and GAAP net loss of $67.45 million. In comparison, last year the company earned revenue of $135 million and had a net profit of $50.02 million. Currently, Seattle Genetics has an average volume of 1.12M.

Based on 12 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $82.44, reflecting a 31.7% upside.

In the last 30 days, insiders have sold $676.3K worth of SGEN shares and purchased $41.9K worth of SGEN shares. The insider sentiment on Seattle Genetics has been negative according to 55 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts